Online citations, reference lists, and bibliographies.
← Back to Search

Phase I And Pharmacokinetics (PK) Of DJ-927, An Oral Taxane, In Patients (Pts) With Advanced Cancers.

S. Syed, M. Beeram, C. Takimoto, J. Jakubowitz, M. Kimura, M. Ducharme, S. Gadgeel, R. D. De Jager, E. Rowinsky, P. LoRusso
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
2028 Background: DJ-927, a novel semi-synthetic taxane and a poor substrate of P-glycoprotein (Pgp), is orally bioavailable and possesses potent anti-tumor activity against Pgp expressing human cancers. Preclinically, DJ-927 is more potent than both paclitaxel and docetaxel. METHODS This first-in-human study assessed the maximum tolerated dose [MTD], dose limiting toxicities [DLT] and PK of DJ-927 administered as a single oral 3-weekly dose. Pts were stratified based on prior therapy into minimally (MP) and heavily (HP) pretreated cohorts. The starting dose of DJ-927, 1.5 mg/m2, was increased in 100% increments until grade 2 toxicities occurred during course 1 and by 50% thereafter, until consistent DLT were observed. RESULTS To date, 40 pts have received 109 courses [median-2; range 1-8] at the following doses: 1.5 mg/m2 [3], 3 mg/m2 [3], 6 mg/m2 [3], 12 mg/m2 [3], 18 mg/m2 [4], 27 mg/m2 [8], 35 mg/m2 [8] and 40 mg/m2 [8]. Demographics: 23 male / 17 female; median [range] age- 57 [31-81]; PS 0 [7], PS 1 [31], and PS 2 [2]. Primary tumors are colorectal [15], breast [4], pancreas [5], renal cell [3], soft tissue sarcoma [3] and others [10]. Minimal drug-related toxicities were observed at doses 5 days duration [7] and grade 3 thrombocytopenia [4] were the predominant hematological toxicities observed at 40 and 35 mg/m2 doses. Non-hematological toxicities included: transient grade 3 peripheral sensory neuropathy after 3 cycles [1] at 27 mg/m2, grade 3 diarrhea and grade 3 mucositis [1] at 40mg/m2. Minor responses were seen in taxane-refractory breast carcinoma [1] and transitional cell carcinoma of the bladder [1]. Disease stabilization for >3 months was noted in 8 pts. Plasma PK of DJ- 927 were dose proportional over the dose range explored. The Cmax, mean (CV%) 58.83 (70.2) μg/L, AUC (inf) 1792.7 (36.4) h*μg/L), clearance/F 45.93 (48.6) L/h, and terminal half-life 175.5 (38.2) h were seen at 40 mg/m2 dose (8). CONCLUSIONS DJ-927 generates predictable systemic drug exposures and has been well tolerated when orally administered. Dose escalation ceased due to DLT in 2/3 MP + 2/5 HP at 40 mg/m2 and 2/6 MP + 2/2 HP at 35 mg/m2. MTD has been defined as 27 mg/m2 for MP and HP patients. [Table: see text].



This paper is referenced by
10.1002/9783527676545.CH04
Taxol, Taxoids, and Related Taxanes
I. Ojima (2014)
10.4155/CLI.13.18
Novel oral taxane therapies: recent Phase I results.
J. P. Flores (2013)
10.1002/med.20239
Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression
S. Nobili (2012)
10.1016/j.clgc.2012.01.009
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
G. Liu (2012)
10.1517/13543770902775713
Microtubule stabilising agents for cancer chemotherapy
Ying-Ze Zhao (2009)
10.1016/S1359-6349(08)71921-9
Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer
M. Aapro (2008)
10.1016/J.CTRV.2007.08.001
Novel cytotoxic drugs: old challenges, new solutions.
G. Ismael (2008)
10.1007/978-1-59745-215-1_15
Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF
C. Takimoto (2007)
10.1517/17460441.2.6.861
New target agents in the treatment of colorectal cancer patients
G. Tonini (2007)
10.1007/978-1-59745-035-5_18
Resistance To Taxanes
L. Greenberger (2006)
10.1053/J.SEMINONCOL.2006.04.006
Novel agents that target tublin and related elements.
E. Rowinsky (2006)
10.1093/ANNONC/MDJ100
Novel formulations of taxanes: a review. Old wine in a new bottle?
K. Hennenfent (2006)
10.1016/J.PATBIO.2005.03.003
Update on tubulin-binding agents.
G. Attard (2006)
10.1177/107327480501200205
Targeted therapies in the treatment of colorectal cancers.
Todd J. Alekshun (2005)
10.1016/J.CRITREVONC.2005.01.006
New cytotoxic agents: a review of the literature.
K. Hotta (2005)
10.1016/S1533-0028(11)70188-8
Highlights From: The 4th International Congress on Colorectal Cancer; Aventura, Florida, October 2005
P. Tyagi (2005)
Semantic Scholar Logo Some data provided by SemanticScholar